Mathieu Victor Paulin, Dorsa Mehrabanpour, Suraj Unniappan, Elisabeth C. R. Snead
{"title":"口服强的松龙可降低健康犬血浆精氨酸抗利尿激素和血清copeptin浓度。","authors":"Mathieu Victor Paulin, Dorsa Mehrabanpour, Suraj Unniappan, Elisabeth C. R. Snead","doi":"10.1111/jvim.17304","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Eight healthy neutered young adult research Beagles.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In our prospective longitudinal study, Beagles were treated with a placebo PO q24h for 15 days (baseline), followed by a 35-day course of prednisolone (2.35-2.75 mg/kg PO q24h) and then abrupt discontinuation of prednisolone. Serial pAVP and sCoP concentrations, urine specific gravity (USG) and calculated plasma osmolality (pOsm<sub>calculated</sub>) were determined during placebo and prednisolone administration, and up to 4 weeks after prednisolone discontinuation. Paired plasma samples for pAVP measurement were obtained in EDTA tubes with (pAVP<sub>P800</sub>) and without (pAVP<sub>EDTA</sub>) a proprietary combination of protease, esterase, and dipeptidyl peptidase-IV inhibitors (BD Biosciences P800).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Mean pAVP<sub>P800</sub> and sCoP concentrations were significantly lower at the end of the prednisolone course (25.8 ± 8.1 pg/mL and 166 pg/mL, range, 131-223) vs baseline (34.1 ± 5.4 pg/mL and 243 pg/mL, range, 157-336; <i>P</i> = .02, <i>P</i> = .02, respectively). Correlations between pAVP<sub>P800</sub> and sCoP (<i>r</i> = .77, <i>P</i> = .001) and pAVP<sub>P800</sub> and USG (<i>r</i> = .61, <i>P</i> = .02) were positive, despite no correlation between pAVP<sub>P800</sub> and pOsm<sub>calculated</sub>, sCoP and pOsm<sub>calculated</sub>, and sCoP and USG. On paired samples, mean pAVP<sub>EDTA</sub> was significantly lower (5.0 ± 2.5 pg/mL) than mean pAVP<sub>P800</sub> (34.1 ± 5.4 pg/mL; <i>P</i> < .0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Orally administered prednisolone led to markedly decreased plasma AVP and serum CoP concentrations despite increased calculated plasma osmolality and stable systolic blood pressure.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744477/pdf/","citationCount":"0","resultStr":"{\"title\":\"Orally administered prednisolone decreases plasma arginine vasopressin and serum copeptin concentrations in healthy dogs\",\"authors\":\"Mathieu Victor Paulin, Dorsa Mehrabanpour, Suraj Unniappan, Elisabeth C. R. Snead\",\"doi\":\"10.1111/jvim.17304\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Animals</h3>\\n \\n <p>Eight healthy neutered young adult research Beagles.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>In our prospective longitudinal study, Beagles were treated with a placebo PO q24h for 15 days (baseline), followed by a 35-day course of prednisolone (2.35-2.75 mg/kg PO q24h) and then abrupt discontinuation of prednisolone. Serial pAVP and sCoP concentrations, urine specific gravity (USG) and calculated plasma osmolality (pOsm<sub>calculated</sub>) were determined during placebo and prednisolone administration, and up to 4 weeks after prednisolone discontinuation. Paired plasma samples for pAVP measurement were obtained in EDTA tubes with (pAVP<sub>P800</sub>) and without (pAVP<sub>EDTA</sub>) a proprietary combination of protease, esterase, and dipeptidyl peptidase-IV inhibitors (BD Biosciences P800).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Mean pAVP<sub>P800</sub> and sCoP concentrations were significantly lower at the end of the prednisolone course (25.8 ± 8.1 pg/mL and 166 pg/mL, range, 131-223) vs baseline (34.1 ± 5.4 pg/mL and 243 pg/mL, range, 157-336; <i>P</i> = .02, <i>P</i> = .02, respectively). Correlations between pAVP<sub>P800</sub> and sCoP (<i>r</i> = .77, <i>P</i> = .001) and pAVP<sub>P800</sub> and USG (<i>r</i> = .61, <i>P</i> = .02) were positive, despite no correlation between pAVP<sub>P800</sub> and pOsm<sub>calculated</sub>, sCoP and pOsm<sub>calculated</sub>, and sCoP and USG. On paired samples, mean pAVP<sub>EDTA</sub> was significantly lower (5.0 ± 2.5 pg/mL) than mean pAVP<sub>P800</sub> (34.1 ± 5.4 pg/mL; <i>P</i> < .0001).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Clinical Importance</h3>\\n \\n <p>Orally administered prednisolone led to markedly decreased plasma AVP and serum CoP concentrations despite increased calculated plasma osmolality and stable systolic blood pressure.</p>\\n </section>\\n </div>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744477/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17304\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17304","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:外源性糖皮质激素过量引起的多尿和多饮的病理生理机制尚不完全清楚。目的:研究健康犬在口服强的松龙之前、期间和之后的血浆AVP (pAVP)和血清CoP (sCoP)浓度。动物:8只健康的阉割的年轻成年研究猎犬。方法:在我们的前瞻性纵向研究中,比格犬接受15天(基线)的安慰剂治疗,随后进行35天的强的松龙疗程(2.35-2.75 mg/kg PO q24h),然后突然停用强的松龙。在安慰剂和泼尼松龙给药期间以及泼尼松龙停药后4周,分别测定了pAVP和sCoP浓度、尿比重(USG)和计算血浆渗透压(posm计算)。在含有(pAVPP800)和不含(pAVPEDTA)的EDTA管中获得用于测量pAVP的成对血浆样品,(pAVPP800)是一种专有的蛋白酶、酯酶和二肽基肽酶- iv抑制剂的组合(BD Biosciences P800)。结果:在强的松龙疗程结束时,pAVPP800和sCoP的平均浓度(25.8±8.1 pg/mL和166 pg/mL,范围,131-223)明显低于基线(34.1±5.4 pg/mL和243 pg/mL,范围,157-336);p =。2, p =。02年,分别)。pAVPP800与sCoP的相关性(r =。77, P = .001), pAVPP800和USG (r = .001)。(61, P = 0.02),尽管pAVPP800与posmcalculate、sCoP与posmcalculate、sCoP与USG无相关性。配对样本中,pAVPEDTA的平均值(5.0±2.5 pg/mL)显著低于pAVPP800的平均值(34.1±5.4 pg/mL);结论及临床意义:口服强的松龙可显著降低血浆AVP和血清CoP浓度,尽管计算血浆渗透压升高,收缩压稳定。
Orally administered prednisolone decreases plasma arginine vasopressin and serum copeptin concentrations in healthy dogs
Background
The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.
Objective
Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.
Animals
Eight healthy neutered young adult research Beagles.
Methods
In our prospective longitudinal study, Beagles were treated with a placebo PO q24h for 15 days (baseline), followed by a 35-day course of prednisolone (2.35-2.75 mg/kg PO q24h) and then abrupt discontinuation of prednisolone. Serial pAVP and sCoP concentrations, urine specific gravity (USG) and calculated plasma osmolality (pOsmcalculated) were determined during placebo and prednisolone administration, and up to 4 weeks after prednisolone discontinuation. Paired plasma samples for pAVP measurement were obtained in EDTA tubes with (pAVPP800) and without (pAVPEDTA) a proprietary combination of protease, esterase, and dipeptidyl peptidase-IV inhibitors (BD Biosciences P800).
Results
Mean pAVPP800 and sCoP concentrations were significantly lower at the end of the prednisolone course (25.8 ± 8.1 pg/mL and 166 pg/mL, range, 131-223) vs baseline (34.1 ± 5.4 pg/mL and 243 pg/mL, range, 157-336; P = .02, P = .02, respectively). Correlations between pAVPP800 and sCoP (r = .77, P = .001) and pAVPP800 and USG (r = .61, P = .02) were positive, despite no correlation between pAVPP800 and pOsmcalculated, sCoP and pOsmcalculated, and sCoP and USG. On paired samples, mean pAVPEDTA was significantly lower (5.0 ± 2.5 pg/mL) than mean pAVPP800 (34.1 ± 5.4 pg/mL; P < .0001).
Conclusions and Clinical Importance
Orally administered prednisolone led to markedly decreased plasma AVP and serum CoP concentrations despite increased calculated plasma osmolality and stable systolic blood pressure.
期刊介绍:
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.